FD-895

FD-895 is a naturally derived 12-membered macrolide polyketide first discovered in 1994 by Taisho Pharmaceutical. It acts as a small molecule spliceosome modulator that specifically targets the SF3B complex (primarily the SF3B1 subunit). By binding to the spliceosome, FD-895 induces widespread mRNA intron retention, which triggers apoptosis in cancer cells through a TP53-independent pathway. It has been extensively studied as a research tool and potential therapeutic candidate for hematologic malignancies such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and acute myeloid leukemia (AML), as well as various solid tumors. FD-895 is the founding member of the pladienolide family of splicing inhibitors, which includes the clinical candidate E7107.

Other names

17S-FD-895